Tech Company Financing Transactions

Dekkun Funding Round

On 1/10/2011, Dekkun raised $9.9 million in financing from HealthCare Ventures and private investors.

Transaction Overview

Company Name
Announced On
1/10/2011
Transaction Type
Venture Equity
Amount
$9,930,400
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Pkwy. 102
Cambridge, MA 02142
USA
Email Address
Not Recorded
Overview
DKN-01, which targets the Dickkopf-1 (DKK-1) protein, is an inhibitor of the canonical Wnt/ß-catenin signaling pathway. DKN-01 is presently being studied in Phase 1 clinical trials in tumors which have been linked to elevated circulating levels of DKK-1 or osteolytic bone disease, including non-small cell lung cancer and multiple myeloma.
Profile
Dekkun LinkedIn Company Profile
Social Media
Dekkun Company Twitter Account
Company News
Dekkun News
Facebook
Dekkun on Facebook
YouTube
Dekkun on YouTube

Management Team

Title
Name
Email & Social
Chief Medical Officer
Steven Landau
  Steven Landau LinkedIn Profile  Steven Landau Twitter Account  Steven Landau News  Steven Landau on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/7/2011: GestureTek venture capital transaction
Next: 1/10/2011: Groupon venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary